Clinical Trials in Philadelphia

Showing 581-600 of 20,904 trials

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

NCT04439175

This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Researchers hope to learn if taselisib will shrink this type of cancer or stop its growth.

Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more

National Cancer Institute (NCI)70 participantsStarted Feb 2016

Philadelphia, Pennsylvania, United States

TERMINATEDPhase 2< 1 mile

PR3-AAV Resilient Remission or PRRR

NCT05376319

The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).

Granulomatosis With PolyangiitisMicroscopic PolyangiitisANCA Associated Vasculitis

Mayo Clinic6 participantsStarted Jun 2023

Boston, Massachusetts, United States • Rochester, Minnesota, United States • Philadelphia, Pennsylvania, United States

RECRUITINGPhase 1/2< 1 mile

A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

NCT07282847

This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).

Pompe Disease (Late-onset)Pompe Disease Late-OnsetLOPD

AskBio Inc12 participantsStarted Apr 2026

Phoenix, Arizona, United States • Irvine, California, United States • Palo Alto, California, United States +7 more locations

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

PR3-AAV Resilient Remission or PRRR

A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

Find Trials by Condition in Philadelphia

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

PROSpect: Prone and Oscillation Pediatric Clinical Trial

Confirm Rx Insertable Cardiac Monitor SMART Registry

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease